Literature DB >> 25215498

SnapShot: FMRP mRNA targets and diseases.

Emanuela Pasciuto1, Claudia Bagni2.   

Abstract

FMRP, or fragile X mental retardation protein is an RNA-binding protein. Mutations in the FMRP protein have been associated with neurological disease as have a number of its mRNA-binding targets. This SnapShot presents 40 bona fide FMRP targets for which mRNA binding and protein regulation have been robustly reported in mammals along with the diseases with which they have been associated.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25215498     DOI： 10.1016/j.cell.2014.08.035

Source DB:  PubMed          Journal:  Cell        ISSN： 0092-8674            Impact factor:   41.582


  26 in total

Review 1.  Advanced technologies for the molecular diagnosis of fragile X syndrome.

Authors:  Flora Tassone
Journal:  Expert Rev Mol Diagn       Date:  2015-10-21       Impact factor: 5.225

2.  Fragile X Syndrome FMRP Co-localizes with Regulatory Targets PSD-95, GABA Receptors, CaMKIIα, and mGluR5 at Fiber Cell Membranes in the Eye Lens.

Authors:  Peter H Frederikse; Anoop Nandanoor; Chinnaswamy Kasinathan
Journal:  Neurochem Res       Date:  2015-08-23       Impact factor: 3.996

Review 3.  Lens Biology is a Dimension of Neurobiology.

Authors:  Peter Frederikse; Chinnaswamy Kasinathan
Journal:  Neurochem Res       Date:  2017-02-04       Impact factor: 3.996

4.  Augmented noncanonical BMP type II receptor signaling mediates the synaptic abnormality of fragile X syndrome.

Authors:  Risa Kashima; Sougata Roy; Manuel Ascano; Veronica Martinez-Cerdeno; Jeanelle Ariza-Torres; Sunghwan Kim; Justin Louie; Yao Lu; Patricio Leyton; Kenneth D Bloch; Thomas B Kornberg; Paul J Hagerman; Randi Hagerman; Giorgio Lagna; Akiko Hata
Journal:  Sci Signal       Date:  2016-06-07       Impact factor: 8.192

5.  Deficits in the activity of presynaptic γ-aminobutyric acid type B receptors contribute to altered neuronal excitability in fragile X syndrome.

Authors:  Ji-Yong Kang; Jayashree Chadchankar; Thuy N Vien; Michelle I Mighdoll; Thomas M Hyde; Robert J Mather; Tarek Z Deeb; Menelas N Pangalos; Nicholas J Brandon; John Dunlop; Stephen J Moss
Journal:  J Biol Chem       Date:  2017-02-17       Impact factor: 5.157

Review 6.  Dysregulation and restoration of translational homeostasis in fragile X syndrome.

Authors:  Joel D Richter; Gary J Bassell; Eric Klann
Journal:  Nat Rev Neurosci       Date:  2015-09-09       Impact factor: 34.870

7.  Altered mitochondrial function in cells carrying a premutation or unmethylated full mutation of the FMR1 gene.

Authors:  Veronica Nobile; Federica Palumbo; Stella Lanni; Valentina Ghisio; Alberto Vitali; Massimo Castagnola; Valeria Marzano; Giuseppe Maulucci; Claudio De Angelis; Marco De Spirito; Laura Pacini; Laura D'Andrea; Rino Ragno; Giulia Stazi; Sergio Valente; Antonello Mai; Pietro Chiurazzi; Maurizio Genuardi; Giovanni Neri; Elisabetta Tabolacci
Journal:  Hum Genet       Date:  2020-01-09       Impact factor: 4.132

Review 8.  Autism spectrum disorder: neuropathology and animal models.

Authors:  Merina Varghese; Neha Keshav; Sarah Jacot-Descombes; Tahia Warda; Bridget Wicinski; Dara L Dickstein; Hala Harony-Nicolas; Silvia De Rubeis; Elodie Drapeau; Joseph D Buxbaum; Patrick R Hof
Journal:  Acta Neuropathol       Date:  2017-06-05       Impact factor: 17.088

9.  Clinical and Molecular Assessment in a Female with Fragile X Syndrome and Tuberous Sclerosis.

Authors:  Carolyn M Yrigollen; Laura Pacini; Veronica Nobile; Reymundo Lozano; Randi J Hagerman; Claudia Bagni; Flora Tassone
Journal:  J Genet Disord Genet Rep       Date:  2016-07-15

10.  Accumulated common variants in the broader fragile X gene family modulate autistic phenotypes.

Authors:  Beata Stepniak; Anne Kästner; Giulia Poggi; Marina Mitjans; Martin Begemann; Annette Hartmann; Sandra Van der Auwera; Farahnaz Sananbenesi; Dilja Krueger-Burg; Gabriela Matuszko; Cornelia Brosi; Georg Homuth; Henry Völzke; Fritz Benseler; Claudia Bagni; Utz Fischer; Alexander Dityatev; Hans-Jörgen Grabe; Dan Rujescu; Andre Fischer; Hannelore Ehrenreich
Journal:  EMBO Mol Med       Date:  2015-12       Impact factor: 12.137
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.